Questcor's Acthar shows positive results for systemic lupus erythematosus Questcor announced that results from the first modern clinical study examining the use of H.P. Acthar Gel in systemic lupus erythematosus has been published in the journal LUPUS. The results reveal that Acthar treatment resulted in significant improvements in certain clinical outcome measures that indicate a reduction of lupus disease activity. The drug was generally well-tolerated during the course of the study.
News For QCOR From The Last 14 Days
Check below for free stories on QCOR the last two weeks.